Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute effects of SGLT2 inhibition on renal oxygenation and autonomic function in type 1 diabetes
2019-004557-92Phase 4Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Primary end-point. Started Jan 2020; status: completed.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2019-004557-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004557-92.